mesalamine has been researched along with Bone Cancer in 1 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One comparing two different dosing regimens for the maintenance of remission in people with ulcerative colitis (CODA), and the other comparing an orally administered treatment to an intravenously administered treatment in preventing skeletal-related events in patients with bone metastases from breast cancer (ZICE)." | 1.46 | The use of randomisation-based efficacy estimators in non-inferiority trials. ( Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gillespie, D | 1 |
| Farewell, D | 1 |
| Barrett-Lee, P | 1 |
| Casbard, A | 1 |
| Hawthorne, AB | 1 |
| Hurt, C | 1 |
| Murray, N | 1 |
| Probert, C | 1 |
| Stenson, R | 1 |
| Hood, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate [NCT00326820] | Phase 3 | 1,404 participants (Actual) | Interventional | 2006-01-31 | Active, not recruiting | ||
| A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis.[NCT00708656] | Phase 3 | 213 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for mesalamine and Bone Cancer
| Article | Year |
|---|---|
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |